Kevin Cureton Takes the Helm at Solésence After a 13-Year Climb

Kevin Cureton became President and CEO of Solésence Inc. (NASDAQ: SLSN) effective September 3, 2025, capping a thirteen-year rise through the company that began when he joined as a sales and marketing vice president in November 2012. That appointment, detailed in a company profile published November 13, 2026, hands the top job to an insider with deep roots in both the company and the personal care chemistry business it competes in.

For practitioners tracking the stock, the signal is continuity. Cureton didn't arrive from outside — he worked his way through nearly every commercial function the company has.

Who is running Solésence now?

Cureton's tenure reads like a ladder built inside the firm. After joining in November 2012 as Vice President of Sales, Marketing and Business Development, he was named Chief Commercial Officer in January 2018. In December 2019 he added operational responsibility as Chief Operating Officer. The September 3, 2025 promotion to President and CEO completed the progression.

That's a four-step climb across roughly thirteen years — a pace of promotion roughly every three to four years. Boards that promote from within typically signal satisfaction with the existing strategy, not a pivot.

What does his background bring to the role?

Cureton carries more than twenty years of chemical industry experience, with most of that time spent in personal care — the sector Solésence serves. His resume includes:

• Twelve years at AMCOL International Corporation, where he founded and served as Managing Director of its skin care and dermatology technology business
• Earlier roles at Air Products, Borden and other entities, where the profile credits "significant contributions"
• A Bachelor of Science in chemical engineering from Carnegie Mellon University
• An MBA from the University of Chicago Booth School of Business

The AMCOL chapter matters most for Solésence watchers. Cureton didn't just work in skin care — he built a skin care and dermatology technology business from scratch and ran it. That's directly adjacent to what a NASDAQ-listed personal care chemistry company does, and it means the new CEO has already sat in the founder-operator seat once before.

What does this change for investors and partners?

The practical question is what an insider-CEO with commercial and operating credentials changes. The honest answer from the record: probably sequencing, not direction. Cureton has run sales, marketing, business development, commercial operations and general operations at Solésence — every lever a CEO pulls was once his direct responsibility. Suppliers and customers dealing with the company are now negotiating with someone who has personally held each of those chairs.

His technical training adds a second layer. A chemical engineer with an MBA from Booth can evaluate product pipeline decisions on both the science and the economics — a combination that matters in an industry where formulation claims and margin discipline collide.

The profile itself is light on forward strategy — it documents the man, not the roadmap. What it establishes is that Solésence's board chose depth over disruption: a leader with two decades in the chemicals trade, a dozen years running a comparable skin care technology business at AMCOL, and thirteen years of institutional knowledge at Solésence itself. Whether that continuity translates into execution under a permanent CEO is the question the company's next results cycle will start to answer.